Cabometyx is under clinical development by Exelixis and currently in Phase II for Gastric Cancer. According to GlobalData, Phase II drugs for Gastric Cancer have a 28% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Cabometyx’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Cabometyx overview

Cabozantinib s-malate (Cabometyx, Aptimetyx) is a s-malate salt form of cabozantinib, acts as an anti-neoplastic agent. It is formulated as film-coated tablets for oral route of administration. Cabometyx is indicated for the treatment of adult and pediatric patients 12 years of age and older with locally advanced or metastatic differentiated thyroid cancer (DTC) that has progressed following prior VEGFR-targeted therapy and who are radioactive iodine-refractory or ineligible. Cabometyx is indicated as monotherapy for the treatment of adult patients with locally advanced or metastatic differentiated thyroid carcinoma (DTC), refractory or not eligible to radioactive iodine (RAI) who have progressed during or after prior systemic therapy.

Cabozantinib is under development for the treatment of metastatic castration-resistant prostate cancer (MCRPC), non-small cell lung cancer, metastatic renal cell carcinoma, urothelial cell cancer, uterine cancer, high grade leiomyosarcoma, adrenocortical carcinoma, gastroesophageal (GE) junction carcinomas, neuroendocrine tumors, melanoma, cervical cancer, triple-negative breast cancer (TNBC), hepatobiliary system tumor, pancreatic cancer, lip cancer, salivary gland cancer, oral cavity (mouth) cancer, oropharyngeal cancer, nasopharyngeal cancer, paranasal sinus and nasal cavity cancer, laryngeal cancer, muscle invasive bladder cancer (MIBC), soft tissue sarcoma, neuroendocrine gastroenteropancreatic tumors (GEP-NET), neuroendocrine carcinoma, metastatic colorectal cancer, esophageal squamous cell carcinoma (ESCC), neuroblastoma, Ewing sarcoma, osteosarcoma, rhabdomyosarcoma, Wilms'' tumor in pediatrics, ovarian cancer, endometrial cancer, gastric cancer, head and neck cancer squamous cell carcinoma, metastatic melanoma, hepatocellular carcinoma, solid tumor, urothelial cell carcinoma, bladder cancer, ureter cancer, urethral cancer, peritoneal cancer, fallopian tube cancer, esophageal cancer. 
The drug candidate was under development for the treatment of recurrent glioblastoma-multiforme (GBM), gastrointestinal stromal tumor (GIST), metastatic hormone-receptor-positive breast cancer, refractory and relapsed multiple myeloma, high-grade glioma, prostate cancer, adenoid cystic carcinoma (ACC), pediatric diffuse intrinsic pontine glioma, medulloblastoma, germ cell tumors.

Exelixis overview

Exelixis is a biopharmaceutical company that focuses on the development and commercialization of small molecule therapies for the treatment of cancer. The company’s marketed products include, Cometriq (cabozantinib), an inhibitor of multiple receptor tyrosine kinases; Cabometyx (cabozantinib) developed for the treatment of patients with advanced renal cell carcinoma (RCC), and hepatocellular carcinoma (HCC). The company’s major pipeline product candidates include zanzalintinib, XB002 and XL102 for the treatment of advanced or metastatic solid tumors, and CBX-12 for advanced metastatic refractory solid tumors. The company has collaborative partnerships with biopharmaceutical companies to advance the development of potential therapies for cancer and other serious diseases. Exelixis is headquartered in Alameda, California, the US.

For a complete picture of Cabometyx’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.